The estimated Net Worth of Mark Plavsic is at least $589 Mille dollars as of 10 January 2023. Dr Plavsic owns over 3,418 units of Fate Therapeutics Inc stock worth over $479,975 and over the last 3 years he sold FATE stock worth over $109,435.
Dr has made over 2 trades of the Fate Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 3,418 units of FATE stock worth $17,910 on 10 January 2023.
The largest trade he's ever made was selling 3,719 units of Fate Therapeutics Inc stock on 5 July 2022 worth over $91,525. On average, Dr trades about 1,427 units every 38 days since 2021. As of 10 January 2023 he still owns at least 123,705 units of Fate Therapeutics Inc stock.
You can see the complete history of Dr Plavsic stock trades at the bottom of the page.
Dr. Mark Plavsic D.V.M., Ph.D. is the Chief Technical Officer at Fate Therapeutics Inc.
Mark's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131.
Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part... e Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
Fate Therapeutics Inc executives and other stock owners filed with the SEC include: